CN113144177A - Surface sterilization antiviral spray and preparation method and application thereof - Google Patents
Surface sterilization antiviral spray and preparation method and application thereof Download PDFInfo
- Publication number
- CN113144177A CN113144177A CN202110189083.3A CN202110189083A CN113144177A CN 113144177 A CN113144177 A CN 113144177A CN 202110189083 A CN202110189083 A CN 202110189083A CN 113144177 A CN113144177 A CN 113144177A
- Authority
- CN
- China
- Prior art keywords
- spray
- value
- oropharyngeal
- hydrogen
- antiviral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01017—Lysozyme (3.2.1.17)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a oropharyngeal surface and hand surface sterilization and antivirus spray which is prepared from lysozyme, tetrapyrachlor, glycyrrhizic acid, acesulfame potassium, menthol and hydrogen-rich water. The invention also discloses the application of the spray as a medicine product for sterilizing and resisting viruses on the surfaces of oropharynx, face and/or hands, in particular to a novel coronavirus SARS-CoV-2. The spray has the characteristics of broad-spectrum antivirus, extremely strong permeability, high action speed, good stability, low toxicity, no corrosiveness, small irritation and good environmental protection property, is particularly easy to form a layer of invisible protective film on oral mucosa, face and skin, particularly on the surface of hands, effectively prevents the infection of bacteria and viruses, and has the effects of long-time bacteriostasis and antivirus, and the product has wide application prospect.
Description
Technical Field
The invention relates to a spray, a preparation method and application thereof, in particular to a oropharyngeal surface and hand surface sterilization antiviral spray, a preparation method and application thereof. Belongs to the technical field of chemical disinfectants.
Background
The presence of harmful microorganisms can cause a number of diseases and, in severe cases, can endanger human life. Disinfection and sterilization are effective measures for maintaining the life safety of human beings. In daily life, various disinfectants are often used.
At present, the active ingredients of the commonly used disinfectants mainly comprise the following substances: oxidizing substances, aldehydes, phenols, alcohols, alkali salts, halogens, surfactants, and the like, but all have disadvantages. The ideal disinfectant has the characteristics of wide bactericidal spectrum, strong bactericidal capacity, high action speed, good stability, low toxicity, corrosiveness, small irritation (no toxicity, no residue, no corrosion or no irritation), easy water dissolution, safety to human and animals, low price, easy obtainment, low environmental pollution degree and the like.
The new coronavirus which has been widely paid attention recently has the phenomenon of human transmission, and has the characteristic of universal susceptibility of human groups, and the transmission paths comprise droplet transmission, contact transmission, aerosol transmission, digestive tract transmission and the like. The transmission of the droplets through the respiratory tract is a main transmission path, viruses exist in the droplets and enter the air through sneezing, coughing and speaking, and small droplets drift in the air in the form of droplet nuclei and can enter mucous membranes of the mouth, nose and eyes at any time to cause virus infection. Therefore, oral and facial epidemic prevention is particularly important, and particularly in hospitals, banks, supermarkets, institutions, enterprises and institutions, movie theaters, troops, entertainment venues, schools, kindergartens, families, hotels, restaurants, airports, wharfs, railway stations and other places, viruses and bacteria are easily transmitted, and public cross infection is caused. Meanwhile, the carelessness of oral hygiene, the use of non-sterilized dental appliances, the passive inhalation of droplets with bacteria and viruses, and the like in life are also important factors causing oral infection and respiratory infectious diseases. In view of the above, the development of new, fast, effective and nontoxic oral and facial bactericidal and antiviral products is particularly urgent.
The oral spray has the characteristics of no need of gargling after use, saving of precious water resources, safety and no irritation, and can be used for facial disinfection, and related products are reported at present. However, most oral care products are mainly used for deodorizing the oral cavity or inhibiting digestive tract pathogenic bacteria such as helicobacter pylori and the like, and rarely relate to the antiviral effect, in particular to the effect of epidemic prevention of novel coronavirus by using the oral and facial bactericidal antiviral spray. Through retrieval, no report is found about the preparation of novel oropharyngeal surface and hand surface bactericidal antiviral spray for epidemic prevention coronavirus by using lysozyme, tetrapyrachlor, glycyrrhizic acid serving as a virus protein receptor ACE2 inhibitor and hydrogen-rich water in a compatible manner and combining acesulfame potassium and menthol.
Disclosure of Invention
Aiming at the defects of the prior art, the invention aims to provide an oropharyngeal surface and hand surface sterilization and antiviral spray, and a preparation method and application thereof.
The invention relates to an oropharyngeal surface and hand surface sterilization and antiviral spray, which is prepared from lysozyme, tetrapyrachlor, glycyrrhizic acid, acesulfame, menthol and hydrogen-rich water, and is characterized in that: the pH value of the spray is 5.5-7, the components of the spray are calculated by 100ml of solution, and the spray contains 300-500 ten thousand units of lysozyme, 0.08-0.12 g of ammonium tetrapyramida, 0.005-0.02 g of glycyrrhizic acid, 0.02-0.05 g of acesulfame potassium, 0.05-0.2 g of menthol and 100ml of hydrogen-rich water.
The preferred implementation formula of the oropharyngeal surface and hand surface sterilizing and antiviral spray is as follows: the pH value of the spray is 6.0-6.8, the components of the spray are calculated by 100ml of solution, and the spray contains 0.2g of lysozyme by mass concentration, namely 400 ten thousand units per 100ml, 0.1g of tetrapyrachlor, 0.01g of glycyrrhizic acid, 0.03g of acesulfame, 0.1g of menthol and 100ml of hydrogen-rich water.
Wherein: the pH of the spray is further preferably 6.3.
The invention relates to a preparation method of an oropharyngeal surface and hand surface sterilizing and antiviral spray, which comprises the following steps:
(1) adding 70-80% hydrogen-rich water into a stirring tank at normal temperature, respectively adding lysozyme, tetrapyrachlor, glycyrrhizic acid, acesulfame potassium and menthol according to the formula, supplementing the rest of hydrogen-rich water, and uniformly stirring;
(2) testing the pH value, determining whether the pH value reaches 5.5-7, and filling if the pH value is between 5.5-7; if the pH value does not reach the standard, the pH value is adjusted to 5.5-7 by citric acid.
The preparation method of the oropharyngeal surface and hand surface sterilizing and antiviral spray preferably comprises the following steps and modes:
(1) adding 70ml of hydrogen-rich water into a stirring tank at normal temperature according to the preparation of a spray with the amount of 100ml, sequentially and respectively adding 0.2g of lysozyme to reach 400 ten thousand units per 100ml, 0.1g of tetrapyrachlor, 0.01g of glycyrrhizic acid, 0.03g of acesulfame potassium, 0.1g of menthol and the hydrogen-rich water to the constant volume of 100ml, and uniformly stirring;
(2) testing the pH value, determining whether the pH value reaches 6.0-6.8, and filling if the pH value is 6.0-6.8; if the pH value does not reach the standard, the pH value is adjusted to 6.0-6.8 by citric acid. Or more preferably 6.3.
The spray provided by the invention can be applied to sterilization and disinfection of oral cavity, pharynx, face and skin, especially hand surface.
The oropharyngeal surface and hand surface sterilization and anti-virus spray is applied as an oropharyngeal, facial and/or skin surface sterilization and anti-virus medicine product.
Preferably, the oropharyngeal surface and hand surface sterilization and anti-virus spray is applied to oropharyngeal, facial or hand surface sterilization and anti-virus medicine products.
In the above application, the bacteria are Escherichia coli 8099, Staphylococcus aureus ATCC6538, Pseudomonas aeruginosa ATCC15442 and Candida albicans ATCC 10231; the virus is respiratory virus or digestive virus.
Wherein: the virus is preferably the novel coronavirus SARS-CoV-2.
In the components of the oropharyngeal surface and hand surface sterilizing and antiviral spray disclosed by the invention, lysozyme and tetrapyrachlor are main sterilizing and antiviral components.
The lysozyme mainly acts on glycoside hydrolase of beta-1, 4 glycosidic bond between N-acetylmuramic acid (NAM) and N-acetylglucosamine (NAC), and acts on peptidoglycan of bacterial cell wall to decompose insoluble mucopolysaccharide of cell wall into soluble glycopeptide, so that cell wall rupture content escapes, and cells are ruptured due to osmotic pressure imbalance, and then die. The antiviral mechanism is as follows: lysozyme can be directly combined with virus protein with negative charge, and forms double salt with DNA, RNA and apoprotein, thereby inactivating virus. In addition, the virus is killed and killed by activating the immune system of the body and regulating the cytotoxicity mediated by lymphocytes and macrophages.
Wherein, the tetrapyrachlor is a cationic quaternary ammonium compound which is used as a surfactant and plays a role in inhibiting and killing by mainly reducing the surface tension. The positive ions adsorb negatively charged bacteria through the actions of electrostatic force, hydrogen bond force, hydrophobic combination between surfactant molecules and protein molecules and the like, and the negatively charged bacteria are gathered on cell walls to generate a chamber resistance effect, so that the bacteria are inhibited in growth and die; at the same time, the hydrophobic alkyl can also act with the hydrophilic group of bacteria to change the permeability of the membrane, so that the lysis is generated, the cell structure is damaged, and the cell is dissolved and killed. The product has the characteristics of high efficiency, low toxicity, difficult influence by pH value change, convenient use, strong stripping effect on a mucus layer, stable chemical performance, good dispersion and corrosion inhibition effects and the like, and in-vitro experimental results show that the product has obvious inhibition and killing effects on various oral pathogenic bacteria and non-pathogenic bacteria.
Glycyrrhizic acid is a novel inhibitor of a coronavirus (SARS-CoV-2) protein receptor ACE2, can be combined with angiotensin converting enzyme 2(ACE2) to block combination of a virus S protein and an ACE2 receptor, and reduces invasion of viruses into epidermal cells of a human body, so that harm of the viruses to the human body is reduced. Neurosurgery of the medical college of Stanford university in USA and the college of traditional Chinese medicine of hong Kong university in United states together published papers, and it was also confirmed that glycyrrhizic acid can bind to ACE2, and thus it can be concluded that glycyrrhizic acid is a potential anti-SARS-CoV-2 compound, and has important value for preventing novel coronavirus (SARS-CoV-2) infection and treating SARS.
Acesulfame potassium and menthol are used to improve the taste of oral antiseptic spray. The addition of glycyrrhizic acid which is a virus protein receptor ACE2 inhibitor in the oropharyngeal surface and hand surface sterilization and anti-virus spray disclosed by the invention is cooperated with lysozyme and tetrapyrachlor, so that the sterilization and anti-virus capabilities of the lysozyme and the tetrapyrachlor can be greatly exerted, and the effect of epidemic prevention of novel coronavirus is well played.
The hydrogen-rich water contains rich hydrogen molecules, and the hydrogen is the only antioxidant substance capable of passing through cell membranes and blood brain barriers, and has incomparable advantages with other antioxidants. After entering the human body, hydrogen in the body is decomposed into hydrogen molecules, namely: active hydrogen. The active hydrogen and active oxygen (oxygen free radical) in human body produce reduction reaction to produce water which is beneficial to human body and has no harm to human body. Active hydrogen is removed, cells are revived, and health is improved.
Hydrogen-rich water with selective antioxidant activity can exert anti-inflammatory effects through a variety of mechanisms. Compared with the traditional inflammation treatment medicine, the hydrogen-rich water has the following advantages: (1) the condition of excessive use does not exist in clinical and animal experiments, and no relevant report of adverse reaction of hydrogen is found at present; (2) hydrogen can selectively remove ROS such as OH and ONOO with strong cytotoxicity without affecting O with weak cytotoxicity2And H2O2(ii) a (3) The hydrogen has small relative molecular mass, can freely pass through various cell membranes and is quickly gathered to a target organ or an organelle to play a role; (4) has no influence on the hemodynamics of the organism and the conventional biochemical indexes such as body temperature, blood pressure, pH value, oxygen partial pressure and the like.
The invention adopts special aluminum can sealing package to obviously improve the stability of hydrogen in water, thereby prolonging the preservation time. The spray has the characteristics of broad-spectrum antivirus, extremely strong permeability, high action speed, good stability, low toxicity, no corrosiveness and small irritation, is particularly easy to form a layer of invisible protective film on oral mucosa, face and skin, particularly on the surface of hands, effectively prevents bacteria and viruses from infecting oral cavity and human body, and has long-term antibacterial and antiviral effects. The oropharyngeal surface and hand surface sterilization and anti-virus spray is convenient to use, is easy to form uniform spray, and is particularly suitable for spraying in the oral cavity and disinfecting the face or the hand.
In summary, the advantages and the obvious effects of the invention are as follows: 1. the antibacterial and antiviral effects of broad spectrum and broad spectrum are achieved by using lysozyme and tetrapyrazamide to simultaneously act on the surfaces of different bacteria and viruses through the double functions of negative ions and positive ions, in particular to novel coronavirus SARS-CoV-2; other product reports of the same mechanism are not seen. 2. The permeability is extremely strong, the action speed is high, and the effect can be achieved within five minutes; 3. the effect lasts for 4-5 hours, and the maximum time can reach 6 hours; 4. a layer of invisible protective film is formed on the oral mucosa, the face and the skin, especially the surface of the hand, so that the infection of bacteria and viruses is effectively blocked; 5. completely non-toxic, degradable and good in environmental protection property; 6. is suitable for disinfection and sterilization of oral cavity, face, skin and other environments.
Detailed Description
The present invention will be described in detail with reference to specific examples. The following examples are merely illustrative of the preferred embodiments of the present invention and are not intended to limit the present invention in any way, and any simple modifications, equivalent changes and modifications made to the embodiments according to the technical spirit of the present invention fall within the scope of the technical solution of the present invention.
Example 1: preparation of oropharyngeal surface and hand surface sterilizing and antiviral spray
Specifically, taking the preparation of 100ml of oropharyngeal surface and hand surface sterilizing and antiviral spray as an example:
(1) adding 70ml of hydrogen-rich water into a stirring tank at normal temperature, sequentially adding 0.2g of lysozyme to reach 400 ten thousand units per 100ml, 0.1g of tetrapyrachlor, 0.01g of glycyrrhizic acid, 0.03g of acesulfame potassium and 0.1g of menthol respectively, and keeping the volume of the hydrogen-rich water to 100ml, and stirring the mixture until the mixture is completely uniform for later use;
(2) testing the pH value, determining whether the pH value reaches 6.0-6.8, and filling if the pH value is 6.0-6.8; if the pH value does not reach the standard, the pH value is adjusted to 6.0-6.8 by citric acid. Or more preferably 6.3.
Example 2: disinfection evaluation of oropharyngeal surface and hand surface bactericidal and antiviral spray
2.1 killing of microorganisms test
2.1.1 preparation of bacterial suspension and bacterial tablet: coli 8099, staphylococcus aureus ATCC6538, pseudomonas aeruginosa ATCC15442, candida albicans ATCC 10231.
2.1.2 tests were conducted according to the sterilization test method specified in the Disinfection technical Specification 2002 edition, and the test results of applying the oral and facial sterilization antiviral spray are shown in Table 1.
Table 1: evaluation of Effect of killing microorganisms
2.2 on-site experiment of oral and facial sterilizing and antiviral spray for oral cavity disinfection
2.2.1 at the site of use, subjects were randomly selected. The test is not less than 30 people.
2.2.2 before disinfection, subjects wash their hands clean, rinse their mouths with clear water, soak them in a test tube containing 10ml of diluent with a sterile cotton swab, squeeze them dry on the tube wall, stretch into the left and inner buccal mucosa of the mouth and wipe them for 10 times with a little effort, rotate the swab while wiping, and after sampling, cut the sampling end of the swab into the tube containing the neutralizing agent in an aseptic operation mode, as a positive control sample.
2.2.3 the oral cavity is disinfected according to the using method of the sterilizing spray, and the action time of the sanitary disinfection of the oral cavity is generally set to be 5 min. After sterilization, the neutralizing agent was used in place of the diluent, and the natural substance remaining on the buccal mucosa on the right inner side of the oral cavity of the subject was sampled once in the same manner as in the positive control group to obtain a test group sample.
2.2.4 the unused neutralizer of the same batch, 1.0ml of each diluent and 1-2 parts of cotton swab are respectively used as negative control group samples.
2.2.5 taking 1.0ml of each sample of the test group, the positive control group and the negative control group, inoculating the samples into the plates by an agar pouring method, inoculating 2 plates into each sample, putting the plates into a 37 ℃ incubator for culturing for 48 hours, and observing the final result.
3.3 evaluation assay
The positive control group should have more bacteria growing, the negative control group should have sterile growth, and the disinfection is qualified when the average killing log value of the oral natural bacteria is more than or equal to 1.00 for 30 persons. The bactericidal effect is shown in table 2.
Table 2: sterilizing effect after 30 people spray disinfectant
Example 3: protection evaluation of oropharyngeal surface and hand surface bactericidal and antiviral spray
3.1 antibacterial circle method for testing antibacterial and bacteriostatic effects of oral and facial antibacterial and antiviral spray
3.1.1 preparation of 100mL LB liquid medium 2 bottles (yeast extract 5g/L, tryptone 10g/L, NaCl 10g/L, agar powder 15g/L), autoclave sterilization at 121 ℃ for 20min, cooling and then inoculating Escherichia coli slant strain 1 and Staphylococcus aureus slant strain 1 respectively. Shaking up, and culturing at 37 ℃ for 1-2 days until the mixture is turbid.
3.1.2 in the clean bench, put into 100mL about 45 ℃ nutrient agar medium, shake, then pour the medium into the dish, wait to solidify, pour 4 culture dishes. 0.2mL of E.coli (8099) suspension and 0.2mL of Staphylococcus aureus (ATCC6538) were pipetted into the medium using a sterile pipette.
3.1.3 taking sterile circular filter paper sheets (5mm) completely soaked by the oral and facial sterilization and antivirus spray, respectively and horizontally putting the sterile circular filter paper sheets into a culture dish containing escherichia coli and a culture dish containing staphylococcus aureus, performing static culture at 37 ℃, and taking out the sterile circular filter paper sheets for 24h/48h/72h to measure the size of a bacteriostatic zone. The results are shown in Table 3.
Table 3: zone of inhibition test
According to the size of the inhibition zone, the oral and facial bactericidal antiviral spray provided by the invention can effectively inhibit the growth of escherichia coli and staphylococcus aureus, and can continuously and stably play a bacteriostatic role.
Example 4: batch preparation of oropharyngeal surface and hand surface sterilization and antivirus spray
The spray comprises 300-500 ten thousand units of lysozyme, 0.08-0.12 g of tetrapyrachlor, 0.005-0.02 g of glycyrrhizic acid, 0.02-0.05 g of acesulfame, 0.05-0.2 g of menthol and 100ml of hydrogen-rich water.
(1) Adding 70-80% hydrogen-rich water into a stirring tank at normal temperature, respectively adding lysozyme, tetrapyrachlor, glycyrrhizic acid, acesulfame potassium and menthol according to the formula, supplementing the rest of hydrogen-rich water, and uniformly stirring;
(2) testing the pH value, determining whether the pH value reaches 5.5-7, and filling if the pH value is between 5.5-7; if the pH value does not reach the standard, the pH value is adjusted to 5.5-7 by citric acid.
Example 5: oropharyngeal surface and hand surface sterilization antiviral spray applied to novel coronavirus nucleic acid detection verification
In order to detect the disinfection effect of the oropharyngeal surface and hand surface sterilization antiviral spray on viruses, 5 nucleic acid samples extracted from novel coronavirus (SARS-CoV-2) nucleic acid positive patients in infectious disease hospitals in Jinan are utilized, and 5% of the oropharyngeal surface and hand surface sterilization antiviral spray is added into SARS-CoV-2 positive RNA in each sample, and the mixture is uniformly mixed. And a novel coronavirus (SARS-CoV-2) nucleic acid detection kit (constant temperature nucleic acid amplification method) (Shandongbaobo Biotechnology Co., Ltd., batch No. 202002001) is used together with a nucleic acid rapid enhancement solution (Shandongbaobo Biotechnology Co., Ltd., batch No. 202002094) to detect the RNA content in each case of SARS-CoV-2 positive RNA, and to verify whether the low-concentration virus RNA exists after disinfection. The specific operation method comprises the following steps:
5.1 Add 2.5. mu.L of nucleic acid template to the reaction tube (5 uL for each of the positive and negative controls).
5.2 Add 2.5. mu.L of B Buffer per reaction tube, cover the tube cap (for multiple reactions, it is recommended to add B Buffer to the inside of the cap of the reaction tube); the reaction tube is inverted up and down for 8 to 10 times and fully mixed; after mixing, the reaction solution is thrown (or quickly centrifuged) to the bottom of the tube and transferred to an amplification zone.
5.3 Using Roche LightCycler480, the reaction solution was transferred to a Roche adapted reaction tube and subjected to amplification reaction.
| Step (ii) of | Temperature of | Time | Number of cycles |
| (ii) incubating | 42℃ | 1min | 1cycle |
| Amplification/detection of fluorescence | 42℃ | 30s | 40ycle |
5.4 nucleic acid amplification
5.5, uniformly mixing the mixed solution by using a pipettor in a blowing and sucking or vortex mode, and instantaneously centrifuging to remove bubbles; can be premixed and then packaged; the operation on ice is not needed. And (3) carrying out reaction on the uniformly mixed system on a qPCR instrument.
Reaction procedure: FAM fluorescence was detected every 30s at 48 ℃ for 20 min. For the reinspection of negative (Ct is more than or equal to 40) samples, the reaction time is recommended to be set to 60min, and the sensitization effect is enlarged.
5.6 more than 20 groups of fluorescence values are collected from each sample, and straight line fitting is carried out by taking the cycle times as an X axis and the fluorescence values as a Y axis to obtain a straight line slope K value. (negative for K value < 500)
TABLE 4 Positive RNA sample nucleic acid test results
| Sample numbering | Ct before addition of the spray of the invention | Ct after adding the spray of the invention | After the spray of the invention is added K |
| 1 | 31 | Not detected out | 45 |
| 2 | 32 | Not detected out | 51 |
| 3 | 29 | Not detected out | 45 |
| 4 | 33 | Not detected out | 56 |
| 5 | 31 | Not detected out | 63 |
From the above results, the results of PCR detection of the novel coronavirus (SARS-CoV-2) nucleic acid positive sample after being treated by the oropharyngeal surface hand surface sterilization antiviral spray of the invention and detection after sensitivity is improved by adding an enhancement solution subsequently are negative. The sterilization and antivirus spray for the oropharyngeal surface and the hand surface has extremely strong destruction effect on SARS-CoV-2 and can be used for killing SARS-CoV-2. This provides a good basis for the virus protection work.
Claims (9)
1. The sterilizing and antiviral spray for the oropharyngeal surface and the hand surface is prepared from lysozyme, tetrapyrachlor, glycyrrhizic acid, acesulfame potassium, menthol and hydrogen-rich water, and is characterized in that: the pH value of the spray is 5.5-7, the components of the spray are calculated by 100ml of solution, and the spray contains 300-500 ten thousand units of lysozyme, 0.08-0.12 g of ammonium tetrapyramida, 0.005-0.02 g of glycyrrhizic acid, 0.02-0.05 g of acesulfame potassium, 0.05-0.2 g of menthol and 100ml of hydrogen-rich water.
2. The oropharyngeal surface and hand surface bactericidal antiviral spray as claimed in claim 1, characterized in that: the pH value of the spray is 6.0-6.8, the components of the spray are calculated by 100ml of solution, and the spray contains 0.2g of lysozyme by mass concentration, namely 400 ten thousand units per 100ml, 0.1g of tetrapyrachlor, 0.01g of glycyrrhizic acid, 0.03g of acesulfame, 0.1g of menthol and 100ml of hydrogen-rich water.
3. The oropharyngeal surface and hand surface bactericidal antiviral spray as claimed in claim 2, characterized in that: the pH value of the spray is 6.3.
4. The process of preparing the sterilizing and antiviral spray for oropharyngeal surface and hand of claim 1 includes the following steps:
(1) adding 70-80% hydrogen-rich water into a stirring tank at normal temperature, respectively adding lysozyme, tetrapyrachlor, glycyrrhizic acid, acesulfame potassium and menthol according to the formula, supplementing the rest of hydrogen-rich water, and uniformly stirring;
(2) testing the pH value, determining whether the pH value reaches 5.5-7, and filling if the pH value is between 5.5-7; if the pH value does not reach the standard, the pH value is adjusted to 5.5-7 by citric acid.
5. The method for preparing the oropharyngeal and hand surface sterilizing and antiviral spray as claimed in claim 4, wherein the spray is prepared by the following steps:
(1) adding 70ml of hydrogen-rich water into a stirring tank at normal temperature according to the preparation of a spray with the amount of 100ml, sequentially and respectively adding 0.2g of lysozyme to reach 400 ten thousand units per 100ml, 0.1g of tetrapyrachlor, 0.01g of glycyrrhizic acid, 0.03g of acesulfame potassium, 0.1g of menthol and the hydrogen-rich water to the constant volume of 100ml, and uniformly stirring;
(2) testing the pH value, determining whether the pH value reaches 6.0-6.8, and filling if the pH value is 6.0-6.8; if the pH value does not reach the standard, the pH value is adjusted to 6.0-6.8 by citric acid.
6. The oropharyngeal and hand surface germicidal and antiviral spray according to claim 1 or 2 for use as a germicidal and antiviral pharmaceutical preparation for oropharyngeal, facial and/or skin surfaces.
7. Use according to claim 6, characterized in that: the oropharyngeal surface and hand surface sterilization and anti-virus spray is applied as an oropharyngeal, facial or hand surface sterilization and anti-virus pharmaceutical product.
8. Use according to claim 6, characterized in that: the bacteria are Escherichia coli 8099, Staphylococcus aureus ATCC6538, Pseudomonas aeruginosa ATCC15442 and Candida albicans ATCC 10231; the virus is respiratory virus or digestive virus.
9. Use according to claim 8, characterized in that: the virus is a novel coronavirus SARS-CoV-2.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110189083.3A CN113144177A (en) | 2021-02-19 | 2021-02-19 | Surface sterilization antiviral spray and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110189083.3A CN113144177A (en) | 2021-02-19 | 2021-02-19 | Surface sterilization antiviral spray and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113144177A true CN113144177A (en) | 2021-07-23 |
Family
ID=76883224
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110189083.3A Pending CN113144177A (en) | 2021-02-19 | 2021-02-19 | Surface sterilization antiviral spray and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113144177A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115136966A (en) * | 2022-05-23 | 2022-10-04 | 中仁药业集团(河南)有限公司 | Antibacterial agent for killing new coronavirus, preparation method and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104958230A (en) * | 2015-06-17 | 2015-10-07 | 天津市聚星康华医药科技有限公司 | Functional oral care composition and application thereof |
| CN111418602A (en) * | 2020-04-17 | 2020-07-17 | 山东莱博生物科技有限公司 | No-clean disinfectant and preparation method and application thereof |
| CN111759805A (en) * | 2020-08-03 | 2020-10-13 | 山东莱博生物科技有限公司 | Oral and facial sterilizing and antiviral spray and preparation method and application thereof |
| CN112135625A (en) * | 2020-04-27 | 2020-12-25 | 广州新创忆药物临床研究有限公司 | Medicine and food for preventing or treating COVID-19 new coronary pneumonia and application thereof |
-
2021
- 2021-02-19 CN CN202110189083.3A patent/CN113144177A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104958230A (en) * | 2015-06-17 | 2015-10-07 | 天津市聚星康华医药科技有限公司 | Functional oral care composition and application thereof |
| CN111418602A (en) * | 2020-04-17 | 2020-07-17 | 山东莱博生物科技有限公司 | No-clean disinfectant and preparation method and application thereof |
| CN112135625A (en) * | 2020-04-27 | 2020-12-25 | 广州新创忆药物临床研究有限公司 | Medicine and food for preventing or treating COVID-19 new coronary pneumonia and application thereof |
| CN111759805A (en) * | 2020-08-03 | 2020-10-13 | 山东莱博生物科技有限公司 | Oral and facial sterilizing and antiviral spray and preparation method and application thereof |
Non-Patent Citations (3)
| Title |
|---|
| A. GREEN等: "In vitro assessment of the virucidal activity of four mouthwashes containing Cetylpyridinium Chloride, ethanol, zinc and a mix of enzyme and proteins against a human coronavirus", 《BIORXIV》 * |
| WEI-JIE GUAN等: "Hydrogen/oxygen mixed gas inhalation improves disease severity and dyspnea in patients with Coronavirus disease 2019 in a recent multicenter，open-label clinical trial", 《JOURNAL OF THORACIC DISEASE》 * |
| 杨秀伟等: "甘草酸的抗病毒作用", 《中国现代中药》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115136966A (en) * | 2022-05-23 | 2022-10-04 | 中仁药业集团(河南)有限公司 | Antibacterial agent for killing new coronavirus, preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1644010B1 (en) | Colloidal silver composition having antimicrobial properties | |
| CN1816330B (en) | Antiseptic compositions, methods and systems | |
| CN102860923B (en) | Nano-silver antibacterial liquid soap and preparation method thereof | |
| CN103410046B (en) | A kind of antimicrobial toilet paper manufacture method | |
| CN103356999B (en) | Novel marine organism washing-free disinfection solution and its application | |
| CN108743702A (en) | A kind of anti-haze poison spray and preparation method thereof | |
| CN101548983B (en) | Skin disinfectant and method of producing the same | |
| CN111543441A (en) | Biological disinfectant | |
| CN102397337A (en) | Traditional Chinese drug disinfectant and preparation method thereof | |
| CN113144177A (en) | Surface sterilization antiviral spray and preparation method and application thereof | |
| CN104604849A (en) | Handwash-free disinfectant and preparation method thereof | |
| CN111418602A (en) | No-clean disinfectant and preparation method and application thereof | |
| CN113995744A (en) | Composition and antibacterial application thereof | |
| CN111759805A (en) | Oral and facial sterilizing and antiviral spray and preparation method and application thereof | |
| CN108935526A (en) | A kind of cordate houttuynia silver ion composite disinfectant | |
| CN111500490A (en) | Microbial type bacteriostatic and odor-removing preparation as well as preparation method and application thereof | |
| CN111567519A (en) | Preparation method of biological disinfectant containing silver ion water | |
| CN111671816A (en) | Plant type no-clean antibacterial disinfectant and preparation method thereof | |
| KR101055079B1 (en) | Eco-friendly hand cleaner and its manufacturing method | |
| CN111742925B (en) | Environment-friendly long-acting washing-free sterilizing disinfectant and preparation and use methods thereof | |
| CN111616148A (en) | High-efficiency disinfectant | |
| CN111467288A (en) | Hand-washing-free disinfectant and preparation method thereof | |
| CN114533798B (en) | Disinfecting composition and preparation method and application thereof | |
| CN104784164A (en) | Protein-based skin cleaning disinfectant and preparation method thereof | |
| CN102698302B (en) | Dedicated vegetal air disinfectant for medical institution |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20210723 |
|
| WD01 | Invention patent application deemed withdrawn after publication |